SecBot SecBot
8-K ·Filed Apr 24, 2026

PDSB

PDS Biotechnology Corp
BULLISH
Impact 6/10
Horizonmonths Processed6mo ago SEC0001140361-26-016684
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Monitor the progress of the Phase 3 VERSATILE-003 trial and upcoming catalysts, including PFS data readout in 2Q 2026 and final data readout in 1H 2027. The positive clinical data could lead to increased investor interest and potential partnerships.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9300
T+0 close · Apr 24, 2026 · via day close
Latest settled
−23.06%
T+60 · $0.7155
Vs SPY
−27.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $0.9300entry
  2. T+1 · 7mo ago +16.13%α +16.61% · $1.08
  3. T+5 · 7mo ago +7.53%α +7.13% · $1.00
  4. T+20 · 6mo ago +18.28%α +13.32% · $1.10
  5. T+60 · 4mo ago −23.06%α −27.84% · $0.7155
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology updated its corporate presentation deck, which includes positive clinical trial data for its lead compound PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer. The presentation highlights a median overall survival of 39.3 months and a 77.4% disease control rate, which is significantly better than the 12-18 month benchmark with current standard of care.

Key Facts

  • PDS Biotechnology updated its corporate presentation deck on April 24, 2026
  • The presentation highlights clinical data for PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer
  • The trial showed a median overall survival of 39.3 months, compared to a 12-18 month benchmark with current standard of care
  • The disease control rate was 77.4%
  • The company has a Phase 3 pivotal trial (VERSATILE-003) underway with FDA alignment on the primary endpoint for accelerated approval
  • The presentation also highlights the company's global IP portfolio with PDS0101 exclusivity through 2041/2042

Financial Impact

The positive clinical data could significantly increase the company's valuation, especially if the Phase 3 trial is successful. The total addressable market in the US is estimated at $1.0B for HPV16+ HNSCC.

revenuemarket capdilution

Risk Factors

  • The company is a clinical-stage biotech with no approved products, so it is highly dependent on the success of its clinical trials
  • The company may need additional financing to fund its operations, which could lead to dilution
  • The company's ability to protect its intellectual property is a key risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-016684
Document: ef20071434_8k.htm0001140361-26-016684
Document: 0001140361-26-016684-index-headers.html0001140361-26-016684
Document: 0001140361-26-016684-index.html0001140361-26-016684
Document: 0001140361-26-016684.txt0001140361-26-016684

Track record

28 reports on PDSB

Performance horizon

6 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026